Precision BioSciences receive $3 million to develop DNE technology

NewsGuard 100/100 Score

Precision BioSciences, Inc., today announced that it has been awarded over $3 million across four government grants. These grants were each awarded to Precision during the 4th Quarter of 2010 and came from the National Institute of Standards and Technology, the Treasury Department, the National Institute of Health, and the State of North Carolina. Together, the grant funding will allow Precision to accelerate development of its proprietary genome engineering technology called the Directed Nuclease Editor (DNE).

“These grants will enable us to further refine applications of the technology, particularly as it pertains to cell line engineering.”

"Precision is poised to utilize DNE technology to address major challenges facing the biomanufacturing industry," said Michael Nicholson, Director of Cell Biology at Precision BioSciences. "These grants will enable us to further refine applications of the technology, particularly as it pertains to cell line engineering."

"We are thrilled to see that so many government funding agencies are recognizing the potential of our DNE technology," stated Derek Jantz, VP of Scientific Development at Precision. "We are grateful to all of those involved in making these awards to Precision."

Source: Precision BioSciences

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses